LeadArtis participates in the second IACT update meeting as well as in the “Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop“ international symposium

01-11-2015

The second IACT assessment meeting took place during November 20-21, 2015 in Pamplona, Spain. LeadArtis is a partner of the Immunostimulatory Agonist Antibodies for Cancer Therapy, a 6.9M€ funding consortium which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). The IACT program aims to translate the agonist IS-Ab concept into clinical treatments (http://www.iact-project.eu/). Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept. An analogous SME-driven effort aims at the development of 2nd generation agonist IS-Abs with superior therapeutic index. In this regard, LeadArtis will apply its TrimerbodyTM technology. The meeting focused on the progress and key capacities.

Additionally, LeadArtis participated in the “Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop” International Symposium (Pamplona 18th-20th, 2015) where numerous worldwide renowned immune-oncology clinical and academic researchers presented and discussed their most recent contributions to the field. The meeting was organized by the Fundación para la Investigación Médica Aplicada – FIMA, Clínica Universidad de Navarra-CUN and Fundación Ramón Arece

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...